

Fresenius Medical Care (FMS)

\$42.93 (As of 08/07/20)

Price Target (6-12 Months): **\$49.00**

Long Term: 6-12 Months

Zacks Recommendation: **Outperform**
(Since: 07/31/20)

Prior Recommendation: Neutral

Short Term: 1-3 Months

Zacks Rank: (1-5) **2-Buy**

Zacks Style Scores: VGM:A

Value: A | Growth: A | Momentum: D

Summary

Fresenius Medical exited the second quarter on a strong note. The company continues to gain from Health Care Products and Services units, which witnessed revenue growth in the quarter under review. The company continues to gain from Health Care Products and Services units, which witnessed revenue growth in the second quarter. A wide range of dialysis products and services instill optimism in the stock. Management expects to undertake meaningful investments in 2020 to capitalize on opportunities and optimize cost base. Per the postulates of the 'Growth Strategy 2020', the company aims to boost revenues to \$28 billion by 2020. Fresenius Medical outperformed the industry in a year's time. However, the company faces intense competition in the field of health care services, and sale of dialysis products, which remains a concern.


Price, Consensus & Surprise



Data Overview

52 Week High-Low	\$46.55 - \$29.17
20 Day Average Volume (sh)	170,734
Market Cap	\$25.6 B
YTD Price Change	16.6%
Beta	1.31
Dividend / Div Yld	\$0.00 / 0.0%
Industry	Medical - Instruments
Zacks Industry Rank	Top 47% (119 out of 252)

Sales and EPS Growth Rates (Y/Y %)



Last EPS Surprise	22.2%
Last Sales Surprise	0.3%
EPS F1 Est- 4 week change	11.4%
Expected Report Date	NA
Earnings ESP	0.0%
P/E TTM	16.5
P/E F1	16.5
PEG F1	2.8
P/S TTM	1.3

Sales Estimates (millions of \$)

	Q1	Q2	Q3	Q4	Annual*
2021					22,558 E
2020	4,950 A	5,017 A	5,554 E	5,768 E	21,456 E
2019	4,694 A	4,883 A	4,913 A	5,073 A	19,576 A

EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2021					\$2.87 E
2020	\$0.52 A	\$0.66 A	\$0.62 E	\$0.69 E	\$2.61 E
2019	\$0.59 A	\$0.52 A	\$0.67 A	\$0.75 A	\$2.53 A

*Quarterly figures may not add up to annual.

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 08/07/2020. The reports text is as of 08/10/2020.

Overview

Based in Bad Homburg, Germany, Fresenius Medical Care AG & Co. KGaA (FMS) is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure.

Formed in 1996 following the merger of the dialysis business of Fresenius AG and the U. S. dialysis service provider, National Medical Care, Fresenius Medical provides products and services across the entire dialysis value chain throughout the World.

Through its network of over 3,600 dialysis clinics across the world, the company offers dialysis services and products in more than 120 countries and employs over 109,000 staffs in more than 50 countries.


Fresenius Medical manufactures a variety of durable medical devices used in the treatment of End Stage Renal Disease (ESRD). Devices like Hemodialysis Machines, Peritoneal Dialysis Machines, Granuflo Concentrate Mixing Tanks and monitoring devices like the Crit-line platform are included in the company's product pipeline.

The company primarily operates in two revenue segments.

The Health Care Services segment: This segment consists of the company's Dialysis Services and the Care-Coordination (non-dialysis laboratory services), which accounted 79% of net revenues in full year 2019.

The Health Care Products segment: This segment comprises of the company's Dialysis machines, dialyzers, dialysis solutions, hemodialysis concentrates, bloodline systems, water treatment systems, dialysis drugs and other medical products. The segment accounted for 21% of net revenues in full year 2019.

Fresenius Medical derives its revenues majorly from four geographical locations - North America, EMEA, Asia-Pacific and Latin America.



Reasons To Buy:

- ▲ **Price Performance:** Shares of Fresenius Medical gained 29.5% compared with the industry's growth of 23.9% in a year's time. Strong global presence, wide range of dialysis products and services, and a robust growth strategy for 2020 continue to favor the stock.
- ▲ **Global Efficiency Program Phase II on Track:** Fresenius Medical has launched the second phase of its Global Efficiency Program (GEP II) in 2018. The program's aim is to identify and realize further efficiency potential and enhance the overall competitiveness of Fresenius Medical. Starting in 2018, GEP II targets to achieve sustained cost improvements of EUR 150 to 200 million per annum by 2020. Per management, the company has already achieved savings around 40% in the first two program years and anticipates achieving the balance 60% of the savings potential in 2020 that will mark the third and final year of the program.
- ▲ **Wide Range of Dialysis Products & Services:** The company provides a wide range of Dialysis products in its own dialysis clinics and to third-party clinics. These include modular machine components, dialyzers, bloodline systems, HD (hemodialysis) solutions, concentrates and water treatment systems.

Wide range of dialysis products, deliberate initiatives for attaining market traction, solid international foothold, strategic acquisitions & divestments are the major growth catalysts

Fresenius Medical offers a wide array of Hemodialysis, Peritoneal dialysis and Acute Dialysis products as well. Earlier, the company sold more than 48,000 dialysis machines worldwide, in addition to 130 million dialyzers. Till date, the company has accounted for almost half of global sales of dialysis products. Around 3 million patients, worldwide, regularly undergo dialysis treatment.

At year-end 2019, home dialysis accounted for 13% of all treatments in the United States. By 2022, the company aims to perform more than 15% of all dialysis treatment in the United States in a home setting and is on track to achieve this target.

In September 2019, the company achieved another milestone in China, with the introduction of the 4,008A dialysis machine. This is a significant step in the market with the largest dialysis patient population in the world.

In the United States, the company is collaborating with other dialysis providers to create isolation clinics and dedicated shifts for COVID positive patients. The primary aim of this collaboration is to keep dialysis patients out of the hospital whenever it is possible. During the second quarter, Fresenius Medical was able to maintain operations in more than 4,000 of its dialysis clinics worldwide without substantial interruption, while minimizing the impact of the pandemic on its staff and patients. Use of telehealth solutions was the primary reason behind this uninterrupted operational performance.

- ▲ **Favorable Tiding on the Regulatory Front:** Fresenius Medical recently announced the FDA device approval for its computer-assisted ultrafiltration control software, which aims to improve fluid management during hemodialysis (HD). This further fortifies Fresenius Medical's foothold in the global renal medical devices and services space.

The ultrafiltration control software is designed to work with its newer HD machines and provide computer-assisted diagnosis. Notably, effective fluid management is critical about creating the best HD treatment.

Growth Strategy 2020: Fresenius Medical has set up a strong long-term objective called the 'Growth Strategy 2020', to chalk out a few strategic initiatives for attaining solid market traction.

Per the postulates of the 'Growth Strategy 2020', Fresenius Medical aims to boost revenues to \$28 billion by 2020, corresponding to an average annual growth rate of around 10%. In this regard revenues increased 7% on a year-over-year basis and reached \$17.9 billion in recent past, driven by strong performance in Health Care Services. Furthermore, management forecasts an increase in revenues in tune with organic growth and acquisitions. At the same time, the company expects high single-digit annual growth in net income by 2020.

In addition to the stock's strong performance in its core dialysis business, Fresenius Medical intends to achieve the 2020 targets by expanding its Care Coordination (non-dialysis segment) as well. The company reconfirmed the mid-term outlook of its 'Growth Strategy 2020' in 2018.

- ▲ **Huge Investments in China & India:** Fresenius Medical plans to invest in designing training facilities, training courses and optimizing facilities to meet increasing demand for home dialysis products and services in the developing economies.
- ▲ **Strong Global Foothold:** Fresenius Medical has a solid market hold in the regions of North America, Europe (EMEA), Asia Pacific and Latin America. To strengthen its market position, the company is resorting to various approaches like enhancing its organic growth and making strategic and suitable acquisitions. The company also aims at aligning its business activities through public-private partnerships in the dialysis business for tapping into new markets in the coming quarters.

In recent past, the company entered the dialysis services market in Israel. Fresenius Medical also expanded its dialysis services business in India by acquiring an 85% stake in Sandor Nephro Services, a dialysis group, offering dialysis treatment and other associated services such as laboratory tests to 308,471 patients in 3,624 dialysis clinics worldwide.

In second-quarter 2020, the company witnessed revenue growth across North America and EMEA. The company achieved an overall organic growth of more than 4%, with strong contributions from North America at 4% and EMEA at 7%. However, the deferral of elective procedures due to the pandemic led to a negative organic growth rate in Care Coordination in Asia Pacific.

- ▲ **Strategic Acquisitions & Partnerships:** Acquisitions have been a key catalyst for the company. In an initiative to boost its long-term strategy or the 'Growth-Strategy 2020', Fresenius Medical already acquired all outstanding shares of NxStage Medical for \$30 a share. Fresenius Medical expects the acquisition to prove accretive to earnings within three years from deal closure. Furthermore, the deal is expected to provide annual pre-tax cost savings of \$80 million to \$100 million over the next three to five years. Fresenius Medical also expects integration costs of about \$150 million over the next three years from the time of announcement last year.

Risks

- **Tough Regulatory Environment:** Fresenius Medical faces a highly regulated environment in almost every country in which it operates. Furthermore, the company has to fulfill specific legal requirements everywhere that includes the tough antitrust regulations. Violating healthcare or other regulations under public law can result in extensive legal repercussions. These include the dismissal of important federal certifications, penalties, fines, recalls, increased costs (for fulfilling regulatory requirements), exclusion from reimbursement programs of the respective government health care system, or even a total or partial ban on business operations.

Adding to the concerns, changes in the law (especially relating to reimbursement) in such a difficult regulatory environment can also impact the company's fundamental business model and the implementation of strategy. Because of the company's significant international exposure, Fresenius Medical is likely to face difficulties while enforcing and collecting trade receivables in foreign legal paradigms. In fact, the inability of certain countries to service their national debt might hamper the company's interests. Notably, concerns associated with the regulatory environment present a low risk to the company in the short-term, and in the mid-term, they present a medium risk to the company.

- **Cutthroat Market Competition:** Fresenius Medical has numerous competitors in the field of health care services as well as the sale of dialysis products. Tough competition in the niche markets is likely to impede the company's sales opportunities and lose market share. However, per management, concerns that arise due to competition represent low risk for the company in the short-term, as well as in the mid-term. The company faces aggressive rivalry from HCA Holdings, DaVita HealthCare and Baxter International.

The problem of competitors copying patents of Fresenius Medical is an added concern, which might arise from inadequate protection for technologies and products developed by the company. This might affect the company's bottom line in the long term.

- **Balance Sheet View:** Fresenius Medical exited second-quarter 2020 with cash and cash equivalents amounting to \$2.08 billion, up from \$1.56 billion sequentially. Meanwhile, the company's long-term debt amounted to \$6.91 billion in the second quarter, compared with \$10.96 billion sequentially. Further, we can see that the current debt level of \$2.63 billion in the quarter has substantially decreased from the preceding quarter's \$4.40 billion. So, both the long-term debt level and current debt level are significantly higher than the company's short-term cash level, which is not particularly good when it comes to company's solvency position, as at least during a year of economic downturn, the company does not have sufficient cash for debt repayment.
-

Last Earnings Report

Fresenius Medical Q2 Earnings & Revenues Top Estimates

Fresenius Medical Care AG & Co. KGaA reported adjusted earnings per share of 66 cents in second-quarter 2020, which beat the Zacks Consensus Estimate of 54 cents by 22.2%. Moreover, the bottom line improved 26.9% year over year.

Revenues improved 2.7% year over year to \$5.02 billion. The top line also surpassed the Zacks Consensus Estimate by 0.3%.

Quarter Ending **06/2020**

Report Date	Jul 30, 2020
Sales Surprise	0.31%
EPS Surprise	22.22%
Quarterly EPS	0.66
Annual EPS (TTM)	2.60

Segmental Details

In the second quarter, Fresenius Medical reported through two segments — Health Care Services and Health Care Products.

Health Care Services revenues improved 5% on a year-over-year basis and 4% at constant currency (cc). The improvement came on the back of growth in same market treatments, and contributions from acquisitions.

Health Care Products revenues climbed 6% year over year and 7% at cc. The upside can primarily be attributed to higher sales of products for acute care treatments and disposables for in-center dialysis.

Geographical Growth

North America

Revenues in the region grew 6% year over year and 4% at cc. On organic basis, sales in the region improved 4%.

EMEA

Revenues in this region increased 6% year over year and 8% cc in the quarter. On organic basis, sales in the region advanced 7%.

Asia-Pacific

Revenues in this region declined 2% year over year and 2% at cc in the reported quarter. On an organic basis, sales in the region fell 1%.

Latin America

Revenues in Latin America fell 2% year over year but rose 24% at cc. Organic growth in region was 18%.

Guidance

The following outlook has been provided after taking into account the neutral net impact of COVID-19 in the first half of 2020.

For 2020, the company continues to expect adjusted revenues and adjusted net income to improve at a mid-to-high-single digit rate.

Valuation

Frenesius' shares are up 16.6% and 29.5% in the year-to-date period and the trailing 12-month periods, respectively. Stocks in the Zacks sub-industry and Zacks Medical Market are up 17.4% and 1% in the year-to-date period, respectively. Over the past year, the Zacks sub-industry and sector are up 23.9% and 9.1%, respectively.

The S&P 500 index is up 4.1% in the year-to-date period and 16.6% in the past year.

The stock is currently trading at 15.5X Trailing 12-months earnings, which compares to 39X for the Zacks sub-industry, 22.4X for the Zacks sector and 22.8X for the S&P 500 index.

Over the past five years, the stock has traded as high as 23.1X and as low as 10.6X, with a 5-year median of 18.6X.

Our Outperform recommendation indicates that the stock will perform above the market. Our \$49 price target reflects 18.5X forward 12-months earnings.

The table below shows summary valuation data for FMS.

Valuation Multiples - FMS					
		Stock	Sub-Industry	Sector	S&P 500
P/E F12M	Current	15.51	39.02	22.37	22.83
	5-Year High	23.09	41.71	23.16	22.83
	5-Year Low	10.57	23.21	15.89	15.25
	5-Year Median	18.56	28.04	18.9	17.55
P/S F12M	Current	1.16	4.43	2.82	3.67
	5-Year High	1.59	4.43	3.41	3.67
	5-Year Low	0.84	2.52	2.22	2.53
	5-Year Median	1.33	3.05	2.9	3.04
P/B TTM	Current	1.75	4.62	4.4	4.58
	5-Year High	2.88	4.77	5.07	4.58
	5-Year Low	1.18	2.75	2.94	2.83
	5-Year Median	2.23	3.88	4.3	3.73

As of 08/07/2020

Industry Analysis Zacks Industry Rank: Top 47% (119 out of 252)



Top Peers

Company (Ticker)	Rec	Rank
DaVita Inc. (DVA)	Outperform	1
American Renal Associates Holdings, Inc (ARA)	Neutral	3
Bristol Myers Squibb Company (BMY)	Neutral	3
Encompass Health Corporation (EHC)	Neutral	3
Eli Lilly and Company (LLY)	Neutral	3
MEDNAX, Inc. (MD)	Neutral	3
Baxter International Inc. (BAX)	Underperform	5
Medtronic PLC (MDT)	Underperform	4

Industry Comparison Industry: Medical - Instruments				Industry Peers		
	FMS	X Industry	S&P 500	BAX	DVA	MDT
Zacks Recommendation (Long Term)	Outperform	-	-	Underperform	Outperform	Underperform
Zacks Rank (Short Term)	2	-	-	5	1	4
VGM Score	A	-	-	B	B	C
Market Cap	25.61 B	136.19 M	23.30 B	40.87 B	10.05 B	134.20 B
# of Analysts	4	2	14	11	7	14
Dividend Yield	0.00%	0.00%	1.76%	1.21%	0.00%	2.32%
Value Score	A	-	-	C	A	C
Cash/Price	0.08	0.09	0.07	0.09	0.30	0.08
EV/EBITDA	6.93	-1.43	13.32	23.28	9.65	18.60
PEG Ratio	2.80	4.42	2.94	2.71	1.29	3.79
Price/Book (P/B)	1.75	3.91	3.19	5.01	4.31	2.64
Price/Cash Flow (P/CF)	7.72	23.20	12.51	16.25	7.30	15.12
P/E (F1)	16.45	45.94	22.02	26.44	12.30	29.33
Price/Sales (P/S)	1.28	4.74	2.53	3.58	0.87	4.64
Earnings Yield	6.08%	-2.54%	4.37%	3.78%	8.13%	3.41%
Debt/Equity	0.47	0.11	0.77	0.80	4.54	0.43
Cash Flow (\$/share)	5.56	-0.13	6.94	4.97	11.28	6.62
Growth Score	A	-	-	B	C	B
Hist. EPS Growth (3-5 yrs)	9.27%	12.40%	10.46%	NA	8.21%	5.13%
Proj. EPS Growth (F1/F0)	8,783.33%	6.71%	-6.80%	-7.77%	23.99%	-25.69%
Curr. Cash Flow Growth	47.56%	5.66%	5.39%	4.10%	19.72%	-9.02%
Hist. Cash Flow Growth (3-5 yrs)	13.72%	11.09%	8.55%	-6.10%	0.89%	7.68%
Current Ratio	1.01	2.66	1.33	2.97	1.35	2.13
Debt/Capital	32.02%	15.18%	44.50%	44.50%	83.54%	30.21%
Net Margin	7.26%	-25.57%	10.13%	8.10%	7.20%	16.56%
Return on Equity	10.50%	-21.62%	14.39%	20.75%	40.78%	12.17%
Sales/Assets	0.54	0.54	0.51	0.62	0.64	0.32
Proj. Sales Growth (F1/F0)	9.68%	0.00%	-1.51%	0.38%	2.08%	-5.08%
Momentum Score	D	-	-	C	D	D
Daily Price Chg	-0.85%	0.00%	0.90%	0.45%	0.10%	3.43%
1 Week Price Chg	-1.66%	0.00%	0.14%	-3.23%	0.07%	0.13%
4 Week Price Chg	1.35%	4.52%	8.95%	-5.79%	3.30%	11.01%
12 Week Price Chg	8.55%	14.58%	18.90%	-7.12%	5.41%	6.64%
52 Week Price Chg	27.81%	0.00%	1.18%	-5.84%	37.77%	-2.18%
20 Day Average Volume	170,734	236,757	2,057,775	3,102,138	832,794	4,642,793
(F1) EPS Est 1 week change	2.36%	0.00%	0.00%	0.29%	8.00%	0.00%
(F1) EPS Est 4 week change	11.44%	0.00%	1.36%	-7.29%	9.18%	-2.69%
(F1) EPS Est 12 week change	7.20%	0.00%	1.57%	-7.29%	9.31%	-32.58%
(Q1) EPS Est Mthly Chg	0.00%	0.00%	0.54%	-10.87%	-2.70%	0.00%

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	A
Growth Score	A
Momentum Score	D
VGM Score	A

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.